SEC Comment Letter 0000000000-22-012352 to Coherus BioSciences, Inc. (CHRS) (CIK 0001512762) (CHRS)
Coherus BioSciences, Inc. (CHRS) (CIK 0001512762)
Date: Nov. 14, 2022 · CIK: 0001512762 · Accession: 0000000000-22-012352
AI Filing Summary & Sentiment
File numbers found in text: 333-268252
Letter
United States securities and exchange commission logo November 14, 2022 McDavid Stilwell Chief Financial Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 Re:Coherus BioSciences, Inc. Registration Statement on Form S-3 Filed November 8, 2022 File No. 333-268252 Dear McDavid Stilwell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Benjamin A. Potter, Esq.
Show Raw Text
United States securities and exchange commission logo
November 14, 2022
McDavid Stilwell
Chief Financial Officer
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
Re:Coherus BioSciences, Inc.
Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268252
Dear McDavid Stilwell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Benjamin A. Potter, Esq.